Panvascular diseases
Conditions
Interventions
Control group:Patients will receive conventional management of coronary heart disease and diabetes. This includes regular outpatient follow-up, doctor interviews, and standard medication and lifestyle
Intervention group:Patients will be fully managed through the Pan-Vascular Disease Management System. The system integrates multi-dimensional health data such as patients' medical history, examination
(2) Remind doctors to review risk factor indicators
(3) Adjust the drug for patients who do not meet the standard.
Sponsors
Fudan University affiliated Zhongshan Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18~75 years old; 2. Meet the diagnostic criteria for type 2 diabetes mellitus: typical diabetes symptoms and any of the following blood glucose indexes meet the diagnostic criteria (random blood glucose >=11.1 mmol/L or fasting blood glucose >=7.0 mmol/L or oral glucose tolerance test (OGTT) 2-hour blood glucose >=11.1 mmol/L or glycosylated hemoglobin (HbA1c) >=6.5%); 3. Meet the diagnostic criteria for coronary heart disease (meet any of them): history of previous myocardial infarction (MI); History of previous revascularization surgery (including percutaneous coronary intervention or coronary artery bypass grafting); Invasive coronaography determines a major vessel stenosis of =50%, or significant stenosis based on physiological criteria, i.e., fractional flow reserve < 0.80.
Exclusion criteria
Exclusion criteria: 1. Acute state of coronary heart disease: within 1 month after ACS or PCI, within 1 month after hospitalization for acute heart failure 2. Acute state of diabetes: 3. Patients with serious diseases, such as malignant tumors, liver cirrhosis, HIV-positive, etc., with a life expectancy of < 1 year; 4. Severe hepatic insufficiency (AST or ALT level more than 3 times the upper limit of normal), severe renal insufficiency (eGFR<30 mL/min/1.73 m^2) 5. Presence of connective tissue disorders (such as Marfan syndrome); 6. Be pregnant or preparing to become pregnant or lactating; 7. Participated in clinical trials of other drugs or medical devices within 1 month before selection; 8. Inability to comply with the study protocol or conduct necessary follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycosylated Hemoglobin(HbA1c);Systolic Blood Pressure(SBP);Diastolic Blood Pressure(DBP);Low-Density Lipoprotein Cholesterol(LDL-C); | — |
Countries
China
Contacts
Public ContactJunbo Ge
Fudan University affiliated Zhongshan Hospital
Outcome results
None listed